Galectin Therapeutics (GALT) Non Operating Income (2010 - 2026)
Galectin Therapeutics' (GALT) quarterly Non Operating Income came in at -$969000.0 in Q1 2026, up 44.12% year-on-year from -$672367.3 in Q1 2025, and up 54.61% quarter-over-quarter from -$2.1 million in Q4 2025.
Galectin Therapeutics (GALT) Non Operating Income (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Non Operating Income history runs 17 years deep, the most recent figure standing at -$969000.0 for Q1 2026.
- On a quarterly basis, Non Operating Income rose 44.12% year-over-year to -$969000.0 in Q1 2026; TTM through Mar 2026 was -$10.0 million, a 121.57% decrease from a year earlier, with the FY2025 full-year figure at -$10.8 million, down 133.01% from the prior year.
- Non Operating Income rose to -$969000.0 in Q1 2026 per GALT's latest filing, from -$2.1 million in the prior quarter.
- Across five years, Non Operating Income topped out at $461000.0 in Q4 2024 and bottomed at -$4.0 million in Q3 2025.
- The 5-year median for Non Operating Income is -$1.1 million (2024), against an average of -$1.2 million.
- Across the five-year window, Non Operating Income plunged 43500.0% in 2023 and surged 205.73% in 2024, its largest moves.
- Year by year, Non Operating Income stood at -$1000.0 in 2022, then plunged by 43500.0% to -$436000.0 in 2023, then jumped by 205.73% to $461000.0 in 2024, then plunged by 563.12% to -$2.1 million in 2025, then jumped by 54.61% to -$969000.0 in 2026.
- Per Business Quant, the three latest GALT Non Operating Income figures stand at -$969000.0 (Q1 2026), -$2.1 million (Q4 2025), and -$4.0 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Galectin Therapeutics | 227.21 Mn | 227.21 Mn | - | -969,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -969,000.00 |
| Dec 31, 2025 | -2.14 Mn |
| Sep 30, 2025 | -3.99 Mn |
| Jun 30, 2025 | -2.90 Mn |
| Mar 31, 2025 | -1.73 Mn |
| Dec 31, 2024 | 461,000.00 |
| Sep 30, 2024 | -2.15 Mn |
| Jun 30, 2024 | -1.08 Mn |
| Mar 31, 2024 | -1.84 Mn |
| Dec 31, 2023 | -436,000.00 |
| Sep 30, 2023 | -1.26 Mn |
| Jun 30, 2023 | -111,000.00 |
| Mar 31, 2023 | -1.19 Mn |
| Dec 31, 2022 | -1,000.00 |
| Sep 30, 2022 | -475,000.00 |
| Jun 30, 2022 | 49,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Dec 31, 2021 | 204,000.00 |
| Sep 30, 2021 | -276,000.00 |
| Jun 30, 2021 | -256,000.00 |